top of page

ASCO 2026: Gilead CMO Dietmar Berger discusses the company's cell therapy and antibody-drug conjugate approaches in oncology, and shares the rationale on four recent acquisitions

  • May 30
  • 1 min read

On the ADC front, he discusses Trodelvy's role in triple-negative breast cancer and the rationale for acquiring Tubulis for its next generation ADC pipeline. Plus, BCMA CAR-T (the acquisition of Arcellx), treating glioblastoma with CAR-T, and the future of in vivo cell therapy.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

Learn more

bottom of page